ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2011.321 etm-02-06-1127 Articles Prognostic significance of microRNA gene polymorphisms in patients with surgically resected colorectal cancer JANGMOON JU1* KIMJONG WOO2* MINKYUNG TAE3 JEONYOUNG JOO3 OHDOYEUN13 KIMNAM KEUN3 Departments of Internal Medicine, and Surgery; Institute for Clinical Research, School of Medicine, CHA University, Seongnam, Republic of Korea Correspondence to: Professor Nam Keun Kim, Institute for Clinical Research, School of Medicine, CHA University, 351 Yatap-dong, Bundang-gu, Seongnam 463-712, Republic of Korea, E-mail: nkkim@cha.ac.kr; namkkim@naver.com

Contributed equally

 November-December 2011 21 7 2011 2 6 1127 1132 28 3 2011 18 7 2011 Copyright © 2011, Spandidos Publications 2011

MicroRNAs (miRNAs) are small 19- to 22-nucleotide sequences of RNA that participate in the regulation of cell differentiation, cell cycle progression and apoptosis. Although single-nucleotide polymorphisms (SNPs) in miRNA regions are considered unlikely to be functionally important, nucleotide variations within the sequences of primary (pri)- or precursor (pre)-miRNAs may affect miRNA processing and ultimately result in the modification of miRNA expression. The aim of this study was to investigate associations between four SNPs in pre-miRNA genes and the survival of colorectal cancer patients. A total of 407 colorectal patients were consecutively enrolled. DNA was extracted from blood specimens, and the hsa-mir-146aC>G, hsa-mir-149C>T, hsa-mir-196a2C>T and hsa-mir-499A>G polymorphisms were genotyped by PCR-RFLP. We were unable to identify independent prognostic SNPs for colorectal cancer. However, the heterozygous TC genotype of the 196a2C>T polymorphism was a significant risk factor for the overall survival of rectal cancer patients (HR=3.554, 95% CI 1.296–9.747, p=0.014). Further large-population studies are warranted to define the 196a2C>T polymorphism as a prognostic factor of rectal cancer.

 colorectal cancer microRNA polymorphism prognosis Introduction

Colorectal cancer is the third most frequently diagnosed cancer and the second leading cause of cancer-related death in Western countries (1). The prognosis of colorectal cancer patients depends on the tumor stage at the time of diagnosis. However, over 57% have regional or distant spread of tumor cells at the time of diagnosis (2). Therefore, it is a significant public health problem worldwide, with specific mortality rates approaching 33% in developed countries (3). In colorectal carcinogenesis, the molecular basis and genetic changes result in a specific phenotype often associated with varying tumor behaviors relevant to the prognosis and the response to specific therapies. As a result, colorectal cancer no longer refers to a single disease, but a heterogeneous group of diseases caused by a differential genetic/epigenetic background. In this respect, many ongoing studies are aimed at assessing biomarkers as potential predictors of prognosis or response to therapy, which will most likely lead to individualized management for patients.

RNA has long been thought to play a relatively passive role in carcinogenesis. However, increasing interest in non-coding genomic sequences has revealed the unappreciated involvement of several classes of non-coding RNA (ncRNA), including antisense RNA (4), small nucleolar RNA (5) and microRNA (miRNA) in carcinogenesis. Among these ncRNAs, many researchers have focused on miRNA due to its frequent dysregulation in cancer. Several studies have revealed that miRNAs, short non-coding RNAs that hybridize to their target mRNAs and repress the expression of encoded proteins, are involved in biological processes, such as cellular differentiation, proliferation, apoptosis and metastasis, through their interactions with intracellular signaling networks (6). miRNAs play critical roles in carcinogenesis by regulating the expression of proto-oncogenes or tumor-suppressor genes (7,8).

The precise mechanisms regulating miRNA expression have not been elucidated, but previous studies strongly support an association between altered miRNA expression and cancer (7,9). Several mechanisms, including gene amplification, deletion, epigenetic alterations and single-nucleotide substitution, have been implicated in altered miRNA expression (10,11). Although single-nucleotide polymorphisms (SNPs) in miRNA regions are considered unlikely to be functionally important (12), nucleotide variations within the sequences of primary (pri)-or precursor (pre)-miRNAs may affect miRNA processing and ultimately result in the modification of miRNA expression (13). Previous studies have reported that nucleotide variations within the seed sequence of the miRNA may affect miRNA processing and lead to reduced miRNA expression (10,13).

However, there were few associations identified for SNPs in pre-miRNA with prognostic significance in colorectal cancer patients (14–16). In the present study, we investigated whether polymorphisms in pre-miRNA genes influence the outcome of patients with surgically resected colorectal cancer. Common (i.e., minor allele frequency >0.05) SNPs located in pre-miRNA and their surrounding regions were surveyed using in silico approaches in the public database, miRBase (17). We then selected four pre-miRNA SNPs (hsa-mir-146a rs2910164 C→G, hsa-mir-196a2 rs11614913 C→T, hsa-mir-499 rs3746444 G→A and hsa-mir-149 rs2292832 C→T) and evaluated their prognostic significance in patients with surgically resected colorectal cancer.

 Materials and methods Study population

Between June 1996 and January 2009, blood samples were collected from 446 consecutive Korean patients who had undergone surgical resection at Bundang CHA Medical Center (Seongnam, Korea). The study only included patients who had undergone surgical resection with a curative intent and who had histologically proven adenocarcinomas [407 patients (91.3% of all colorectal cancer patients)]. The American Joint Committee on Cancer: Classification and Stage Groupings 6th edition was used for tumor assessment. We retrospectively obtained information concerning the date of diagnosis, pathological stage, relapse and death. All study subjects provided written consent and were all ethnic Koreans. The study protocol was approved by the Institutional Review Board of Bundang CHA Medical Center, Seongnam, Republic of Korea.

 Genotyping

DNA was extracted from leukocytes using a G-DEX™ II Genomic DNA Extraction kit (Intron Biotechnology, Seongnam, Korea), according to the manufacturer's instructions. The hsa-mir-146aC>G, hsa-mir-149C>T, hsa-mir-196a2C>T and hsa-mir-499A>G polymorphisms were analyzed by PCR-RFLP assays. Primer sequences for amplification were hsa-mir-146aC>G, forward 5′-CAT GGG TTG TGT CAG TGT CAG AGC T-3′ and reverse 5′-TGC CTT CTG TCT CCA GTC TTC CAA-3′; hsa-mir-149C>T, forward 5′-TGT CTT CAC TCC CGT GCT TGT CC-3′ and reverse 5′-TGA GGC CCG AAA CAC CCG TA-3′; hsa-mir-196a2C>T, forward 5′-CCC CTT CCC TTC TCC TCC AGA TA-3′ and reverse 5′-CGA AAA CCG ACT GAT GTA ACT CCG-3′, and hsa-mir-499A>G, forward 5′-CAA AGT CTT CAC TTC CCT GCC A-3′ and reverse 5′-GAT GTT TAA CTC CTC TCC ACG TGA TC-3′ [contains a mismatch sequence (underlined)]. The annealing temperature was 58°C. The hsa-mir-146aC>G, hsa-mir-149C>T and the hsa-mir-196a2C>T polymorphisms were digested at 37°C for 16 h with SacI, AluI and MspI, respectively, and 499A>G polymorphism was digested at 50°C for 16 h with BclI (New England BioLabs, Beverly, MA, USA). The reaction product (12 μl) was run on a 3.0% agarose gel, stained with ethidium bromide and directly visualized under ultraviolet illumination. Approximately 10% of the PCR reactions for the four miRNA polymorphisms were randomly repeated, and the results were checked for concordance with DNA sequencing using an automatic sequencer (ABI3730xl DNA Analyzer; Applied Biosystems, Foster City, CA, USA). The concordance of the quality control samples was 100%.

 Statistical analysis

The genotypes for each SNP were analyzed as a three group categorical variable (reference model) and were also grouped according to the dominant and recessive model. The genotype specific risks were estimated as odds ratios (OR) with associated 95% confidence intervals (95% CI) by logistic regression analysis and were adjusted for age, gender, differentiation, tumor site, chemotherapy and stage. The overall survival (OS) and relapse-free survival (RFS) were compared using the Kaplan-Meier method, and the potential variables were verified by multivariate analysis using a Cox regression model. All tests were two-tailed, and a p-value of <0.05 was taken to indicate a significant difference. All statistical calculations were performed using SPSS software (ver. 17; SPSS Inc., Chicago, IL, USA).

 Results Patient characteristics

The 407 patients were comprised of 227 men and 180 women, and the mean age was 61.4 years (SD=12.4). Two hundred and thirty-eight patients (58.5%) had colon cancer and 169 patients (70.7%) had rectal cancer. Regarding histological differentiation, 353 patients (86.7%) had moderately differentiated cancer, 31 patients (7.6%) had well-differentiated cancer and 23 patients (5.7%) had poorly differentiated cancer. Pathological staging after curative resection was as follows: stage I for 38 (9.3%), stage II for 188 (44.2%), stage III for 149 (36.6%) and stage IV for 40 (9.8%) patients. Three hundred and forty-eight (85.5%) patients received adjuvant chemotherapy, while 59 (14.5%) patients had non-adjuvant chemotherapy. At the median follow-up duration of 41 months (range 4–182), the estimated 4-year OS and RFS rates for all patients were 79.1 and 78.0%, respectively. A summary of the baseline characteristics of the study subjects is shown in Table I.

 Survival rate according to genotype in colorectal cancer

The four pre-miRNA SNPs of the pre-miRNA-related genes were successfully amplified in all patients. The genotype frequencies of the miRNA polymorphisms also conformed to Hardy-Weinberg equilibrium (p>0.05). The associations between the genotypes of the four pre-miRNA SNPs in pre-miRNAs and the survival of all colorectal cancer patients are shown in Table II. In the univariate analysis of the OS, the four SNPs were not shown to have a significant effect on the 4-year OS. The multivariate Cox proportional analysis produced the same results. When we analyzed the OS by the dominant and recessive model, there were no significant associations of OS with the four pre-miRNA SNPs. In the multivariate Cox proportional analysis of the RFS, none of the four pre-miRNA SNPs were shown to have a significant effect on RFS. When we analyzed the RFS by the dominant and recessive model, there was no significant association of RFS with the four pre-miRNA SNPs.

 Survival rate according to genotype in rectal cancer

Table III shows the association between survival of rectal cancer patients and the four pre-miRNA SNPs. No significant association of OS and RFS with the hsa-mir-146a, hsa-mir-149 or hsa-mir-499 was detected. However, hsa-mir-196a2 TC was associated with a significantly unfavorable OS rate (HR=3.554, 95% CI 1.296–9.747, p=0.014). Also, when the OS was analyzed by the dominant model (TT vs. TC+CC), there were significant associations of unfavorable OS with the hsa-mir-196a2 C allele (HR=3.093, 95% CI 1.139–8.399, p=0.028). In the multivariate Cox proportional analysis of the RFS, none of the four pre-miRNA SNPs were shown to have a significant effect on RFS.

 Discussion

In the present study, we investigated whether four pre-miRNA SNPs are related to the prognosis of colorectal cancer in 407 colorectal cancer patients whose tumors had been surgically resected with a curative intent. The result showed that the hsa-mir-146aC>G, hsa-mir-149C>T, hsa-mir-196a2C>T and hsa-mir-499A>G polymorphisms were not associated with the prognosis of surgically resected colorectal cancer in the Korean population. However, in the subset analysis by tumor site, we found that the heterozygous TC genotype of the 196a2C>T polymorphism was a significant risk factor for 4-year OS, but not for RFS. To our knowledge, this is the first study to provide evidence that the 196a2C>T polymorphism is associated with the prognosis of rectal cancer.

Polymorphisms in miRNA-related genes may alter the expression levels of mature miRNAs, with consequences on the regulation of target genes that affect cancer risk or prognosis. Although it is not possible to define the exact mechanisms of these effects, multiple mechanisms, including cell proliferation, differentiation, apoptosis and drug resistance, are involved in the regulation of mature miRNA expression. In a previous study, Hu et al (15) reported that survival was significantly decreased in 663 patients with non-small cell lung cancer who were homozygous for CC genotype in hsa-mir-196a2. Also, in the genotype-phenotype correlation analysis of 23 human lung cancer tissue samples, homozygous CC genotype was associated with a statistically significant increase in mature hsa-mir-196a expression, but not with changes in the levels of the precursor, suggesting enhanced processing of the pre-miRNA to its mature form. However, this association was not found for the other SNPs, including hsa-mir-146aC>G, hsa-mir-149C>T and hsa-mir-499A>G.

In colorectal cancer, recent studies have shown an association between SNPs in miRNA-related genes and carcinogenesis, treatment response and prognosis. Landi et al (18) found that two SNPs (rs17281995 in CD86 and rs1051690 in INSR) were associated with the risk of colorectal cancer in a Czech population. Moreover, similar results were shown in a pooled analysis of the Czech and Spanish populations (19). Polymorphisms in miRNA genes were found to be correlated with treatment response in colon cancer patients. SNPs rs7372209 and rs1834306 in pri-miR26a-1 and pri-miR-100, respectively, were correlated with tumor response in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan (20). Moreover, a let-7 miRNA-binding site polymorphism in the 3′-untranslated region of the KRAS gene was also found to be positively related to cetuximab responsiveness in wild-type KRAS patients with metastatic colorectal cancer (21,22). Recently, Lee et al (16) investigated the association between survival and 40 polymorphisms of miRNA-related genes in 427 Koreans. This was the first study to evaluate the role of miRNA SNPs in the clinical outcomes of colorectal cancer patients. However, none of the 40 miRNA-related gene SNPs were found to be an independent prognostic marker. The results of the present study are consistent with those results.

Recent studies have reported that the hsa-mir-196a2 C allele is associated with increased risk of various types of cancers. Hoffman et al (23) and Hu et al (24) reported that the C allele is significantly associated with increased breast cancer risk. Also, Tian et al (25) reported that the hsa-mir-196a2 CC genotype is significantly associated with increased lung cancer risk in Chinese individuals. Furthermore, other epidemiological studies have reported the association of the C allele with increased risk of congenital heart disease (26), hepatocellular carcinoma (27) and gastric cancer (28). To our knowledge, there have been only two studies that have investigated the prognostic impact of the hsa-mir-196a2 polymorphism in colorectal cancer (14,16). Consistent with our result, these studies also failed to identify any significance of the hsa-mir-196a2 C polymorphism as a prognostic biomarker. Notably, in this study we found that the hsa-mir-196a2 TC genotype was a significant risk factor for 4-year OS in rectal cancer patients. Also, in the dominant model (TT vs. TC+CC), there were significant associations of unfavorable OS with the hsa-mir-196a2 allele (HR=3.093, 95% CI 1.139–8.399, p=0.028). However, since rectal cancer patients are a relatively small proportion of all colorectal cancer patients, we should be careful when interpreting this result. Larger population studies are warranted to define the association between the hsa-mir-196a2 polymorphism and the prognosis of rectal cancer.

Several previous studies have shown that the altered expression of certain miRNAs is unique to colorectal cancer. In this respect, there is increased interest in the association between miRNA expression in tumors and prognosis, both with regards to treatment response rate and to survival. Although it is not possible at this time to further define the mechanisms through which these SNPs affect prognosis, several studies have reported a correlation between miRNA expression and the survival of various types of malignancies, including lung, breast, prostate cancer and acute myeloid leukemia (29–32). Particularly for colorectal cancer, miRNA-21 has been correlated with poor survival (33). Furthermore, miRNA-106, miRNA-20, miRNA-106a, miRNA-200c and miRNA-203 were identified as possible prognostic biomarkers (33,34). By contrast, Schepeler et al (35) showed that high expression of miRNA-320 and miRNA-498 are associated with longer progression-free survival compared to low expression. Based on this evidence, when we measure miRNA expression in combination with conventional prognostic markers, such as tumor size, metastasis, tumor invasion and differentiation grade, we may more precisely predict the prognosis of colorectal cancer patients. Further study of miRNA expression may provide valuable knowledge on new potential targets for therapy.

In conclusion, we investigated the relationship of four SNPs in pre-miRNA genes with prognosis in surgically resected colorectal cancer patients. We did not identify independent prognostic SNPs for colorectal cancer. However, we found that the heterozygous TC genotype of the 196a2C>T polymorphism was a significant risk factor for OS in rectal cancer patients. Further large-population studies are warranted to define the 196a2C>T polymorphism as a prognostic factor for rectal cancer.

 Acknowledgments

This study was supported, in part, by the National Research Foundation of Korea Grant funded by the Korean Government (2009-0075784), and by the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093821).

 References JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin592252492009 FigueredoACoombesMEMukherjeeSAdjuvant therapy for completely resected stage II colon cancerCochrane Database Syst RevCD0053902008 CunninghamDAtkinWLenzHJLynchHTMinskyBNordlingerBStarlingNColorectal cancerLancet375103010472010 YuWGiusDOnyangoPMuldoon-JacobsKKarpJFeinbergAPCuiHEpigenetic silencing of tumour suppressor gene p15 by its antisense RNANature4512022062008 DongXYGuoPBoydJSunXLiQZhouWDongJTImplication of snoRNA U50 in human breast cancerJ Genet Genomics364474542009 ChenCZMicroRNAs as oncogenes and tumor suppressorsN Engl J Med353176817712005 CalinGACroceCMMicroRNA signatures in human cancersNat Rev Cancer68578662006 Esquela-KerscherASlackFJOncomirs – microRNAs with a role in cancerNat Rev Cancer62592692006 LuJGetzGMiskaEAAlvarez-SaavedraELambJPeckDSweet-CorderoAEbertBLMakRHFerrandoAADowningJRJacksTHorvitzHRGolubTRMicroRNA expression profiles classify human cancersNature4358348382005 DuanRPakCJinPSingle nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNAHum Mol Genet16112411312007 LujambioARoperoSBallestarEFragaMFCerratoCSetienFCasadoSSuarez-GauthierASanchez-CespedesMGitASpiteriIDasPPCaldasCMiskaEEstellerMGenetic unmasking of an epigenetically silenced microRNA in human cancer cellsCancer Res67142414292007 SaundersMALiangHLiWHHuman polymorphism at microRNAs and microRNA target sitesProc Natl Acad Sci USA104330033052007 IwaiNNarabaHPolymorphisms in human pre-miRNAsBiochem Biophys Res Commun331143914442005 ChenHSunLYChenLLZhengHQZhangQFA variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in ChineseIntern Med JJan.172011(E-pub ahead of print). HuZChenJTianTZhouXGuHXuLZengYMiaoRJinGMaHChenYShenHGenetic variants of miRNA sequences and non-small cell lung cancer survivalJ Clin Invest118260026082008 LeeHCKimJGChaeYSSohnSKKangBWMoonJHJeonSWLeeMHLimKHParkJYChoiGSJunSHPrognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancerJ Cancer Res Clin Oncol136107310782010 Griffiths-JonesSThe microRNA registryNucleic Acids Res32D109D1112004 LandiDGemignaniFNaccaratiAPardiniBVodickaPVodickovaLNovotnyJForstiAHemminkiKCanzianFLandiSPolymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancerCarcinogenesis295795842008 LandiDMorenoVGuinoEVodickaPPardiniBNaccaratiACanzianFBaraleRGemignaniFLandiSPolymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancerMutat ResOct.302010(E-pub ahead of print). BoniVZarateRVillaJCBandresEGomezMAMaielloEGarcia-FoncillasJArandaERole of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecanPharmacogenomics JJune292010(E-pub ahead of print). GrazianoFCanestrariELoupakisFRuzzoAGalluccioNSantiniDRocchiMVincenziBSalvatoreLCremoliniCSpotoCCatalanoVD'EmidioSGiordaniPToniniGFalconeAMagnaniMGenetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanPharmacogenomics J104584642010 ZhangWWinderTNingYPohlAYangDKahnMLurjeGLabonteMJWilsonPMGordonMAHu-LieskovanSMauroDJLangerCRowinskyEKLenzHJA let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyAnn Oncol221041092011 HoffmanAEZhengTYiCLeadererDWeidhaasJSlackFZhangYParanjapeTZhuYmicroRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysisCancer Res69597059772009 HuZLiangJWangZTianTZhouXChenJMiaoRWangYWangXShenHCommon genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese womenHum Mutat3079842009 TianTShuYChenJHuZXuLJinGLiangJLiuPZhouXMiaoRMaHChenYShenHA functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in ChineseCancer Epidemiol Biomarkers Prev18118311872009 XuJHuZXuZGuHYiLCaoHChenJTianTLiangJLinYQiuWMaHShenHChenYFunctional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese populationHum Mutat30123112362009 QiPDouTHGengLZhouFGGuXWangHGaoCFAssociation of a variant in MIR196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infectionHum Immunol716216262010 PengSKuangZShengCZhangYXuHChengQAssociation of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese populationDig Dis Sci55228822932010 IorioMVFerracinMLiuCGVeroneseASpizzoRSabbioniSMagriEPedrialiMFabbriMCampiglioMMenardSPalazzoJPRosenbergAMusianiPVoliniaSNenciICalinGAQuerzoliPNegriniMCroceCMMicroRNA gene expression deregulation in human breast cancerCancer Res65706570702005 PorkkaKPPfeifferMJWalteringKKVessellaRLTammelaTLVisakorpiTMicroRNA expression profiling in prostate cancerCancer Res67613061352007 SchwindSMaharryKRadmacherMDMrozekKHollandKBMargesonDWhitmanSPHickeyCBeckerHMetzelerKHPaschkaPBaldusCDLiuSGarzonRPowellBLKolitzJECarrollAJCaligiuriMALarsonRAMarcucciGBloomfieldCDPrognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyJ Clin Oncol28525752642010 TakamizawaJKonishiHYanagisawaKTomidaSOsadaHEndohHHaranoTYatabeYNaginoMNimuraYMitsudomiTTakahashiTReduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survivalCancer Res64375337562004 SchetterAJLeungSYSohnJJZanettiKABowmanEDYanaiharaNYuenSTChanTLKwongDLAuGKLiuCGCalinGACroceCMHarrisCCMicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinomaJAMA2994254362008 XiYFormentiniAChienMWeirDBRussoJJJuJKornmannMPrognostic values of microRNAs in colorectal cancerBiomark Insights21131212006 SchepelerTReinertJTOstenfeldMSChristensenLLSilahtarogluANDyrskjotLWiufCSorensenFJKruhofferMLaurbergSKauppinenSOrntoftTFAndersenCLDiagnostic and prognostic microRNAs in stage II colon cancerCancer Res68641664242008 Tables

Baseline characteristics of study subjects (n=407).

Characteristics n (%)
Age, mean±SD in years 61.4±12.4
Gender, male/female 227/180
Primary tumor site
  Colon 238 (58.5)
  Rectum 169 (41.5)
Histological differentiation
  Well 31 (7.6)
  Moderate 353 (86.7)
  Poor 23 (5.7)
Stage
  0/I 38 (9.3)
  II 180 (44.2)
  III 149 (36.6)
  IV 40 (9.8)
Adjuvant chemotherapy
  No 59 (14.5)
  Yes 348 (85.5)
Relapse-free survival rate (4-year) 78.0
Overall survival rate (4-year) 79.1

Survival rate according to genotype in colorectal cancer.

Genotype OS
RFS
n (%) Adjusted HRa (95% CI) p-value n (%) Adjusted HRa (95% CI) p-value
hsa-mir-146aC>G
  CC 137 (33.7) 1.000 (Ref.) 135 (34.5) 1.000 (Ref.)
  GC 217 (53.3) 1.203 (0.746–1.939) 0.452 205 (52.5) 1.128 (0.702–1.813) 0.621
  GG 53 (13.0) 0.854 (0.384–1.899) 0.701 51 (13.0) 1.494 (0.752–2.970) 0.255
  CC 137 (33.7) 1.000 (Ref.) 135 (34.5) 1.000 (Ref.)
  GC/GG 270 (66.3) 1.141 (0.715–1.822) 0.582 256 (65.5) 1.186 (0.751–1.874) 0.466
  CC/GC 354 (87.0) 1.000 (Ref.) 340 (87.0) 1.000 (Ref.)
  GG 53 (13.0) 0.757 (0.365–1.571) 0.457 51 (13.0) 1.386 (0.748–2.568) 0.302
hsa-mir-149C>T
  TT 194 (47.7) 1.000 (Ref.) 185 (47.3) 1.000 (Ref.)
  TC 168 (41.2) 1.008 (0.640–1.588) 0.973 163 (41.7) 1.201 (0.759–1.900) 0.438
  CC 45 (11.1) 0.990 (0.475–2.062) 0.978 43 (11.0) 0.903 (0.427–1.908) 0.790
  TT 194 (49.7) 1.000 (Ref.) 185 (47.3) 1.000 (Ref.)
  TC/CC 213 (52.3) 1.004 (0.654–1.542) 0.985 206 (52.7) 1.134 (0.731–1.761) 0.576
  TT/TC 362 (88.9) 1.000 (Ref.) 348 (89.0) 1.000 (Ref.)
  CC 45 (11.1) 0.986 (0.487–1.995) 0.969 43 (11.0) 0.822 (0.405–1.665) 0.588
hsa-mir-196a2C>T
  TT 111 (27.3) 1.000 (Ref.) 107 (27.4) 1.000 (Ref.)
  TC 195 (47.9) 1.080 (0.631–1.850) 0.780 189 (48.3) 0.763 (0.445–1.311) 0.330
  CC 101 (24.8) 1.070 (0.574–1.993) 0.832 95 (24.3) 0.998 (0.555–1.794) 0.995
  TT 111 (27.3) 1.000 (Ref.) 107 (27.4) 1.000 (Ref.)
  TC/CC 296 (72.7) 1.077 (0.649–1.788) 0.776 284 (72.6) 0.845 (0.514–1.387) 0.507
  TT/TC 306 (75.2) 1.000 (Ref.) 296 (75.7) 1.000 (Ref.)
  CC 101 (24.8) 1.017 (0.611–1.692) 0.948 95 (24.3) 1.187 (0.732–1.923) 0.490
hsa-mir-499A>G
  AA 259 (63.6) 1.000 (Ref.) 250 (63.9) 1.000 (Ref.)
  AG 137 (33.7) 1.020 (0.641–1.624) 0.933 130 (33.3) 0.939 (0.576–1.531) 0.801
  GG 11 (2.7) 1.135 (0.275–4.682) 0.862 11 (2.8) 1.707 (0.524–5.562) 0.377
  AA 259 (63.6) 1.000 (Ref.) 250 (63.9) 1.000 (Ref.)
  AG/GG 148 (36.4) 1.027 (0.652–1.619) 0.909 141 (36.1) 0.983 (0.613–1.578) 0.944
  AA/AG 396 (97.3) 1.000 (Ref.) 380 (97.2) 1.000 (Ref.)
  GG 11 (2.7) 1.127 (0.276–4.600) 0.869 11 (2.8) 1.752 (0.547–5.616) 0.348

OS, overall survival; RFS, relapse-free survival; HR, hazard ratio.

Percentage of patients adjusted for age, gender, tumor site, differentiation, chemotherapy and stage.

Survival rate according to genotype in rectal cancer.

Genotype OS
RFS
n (%) Adjusted HRa (95% CI) p-value n (%) Adjusted HRa (95% CI) p-value
hsa-mir-146aC>G
  CC 62 (36.7) 1.000 (Ref.) 61 (37.9) 1.000 (Ref.)
  GC 84 (49.7) 1.585 (0.718–3.501) 0.257 78 (48.4) 1.139 (0.558–2.324) 0.723
  GG 23 (13.6) 0.638 (0.171–2.378) 0.506 22 (13.7) 0.799 (0.218–2.924) 0.735
  CC 62 (36.7) 1.000 (Ref.) 61 (37.9) 1.000 (Ref.)
  GC/GG 107 (63.3) 1.337 (0.618–2.893) 0.463 100 (62.1) 1.089 (0.540–2.196) 0.813
  CC/GC 146 (86.4) 1.000 (Ref.) 139 (86.3) 1.000 (Ref.)
  GG 23 (13.6) 0.476 (0.144–1.572) 0.226 22 (13.7) 0.733 (0.220–2.446) 0.615
hsa-mir-149C>T
  TT 82 (48.5) 1.000 (Ref.) 77 (47.8) 1.000 (Ref.)
  TC 65 (38.5) 1.094 (0.542–2.210) 0.803 63 (39.1) 1.136 (0.545–2.370) 0.735
  CC 22 (13.0) 0.640 (0.212–1.930) 0.430 21 (13.0) 0.664 (0.234–1.885) 0.444
  TT 82 (48.5) 1.000 (Ref.) 77 (47.8) 1.000 (Ref.)
  TC/CC 87 (51.5) 0.951 (0.491–1.840) 0.881 84 (52.2) 0.977 (0.486–1.964) 0.949
  TT/TC 147 (87.0) 1.000 (Ref.) 140 (87.0) 1.000 (Ref.)
  CC 22 (13.0) 0.615 (0.213–1.777) 0.372 21 (13.0) 0.618 (0.237–1.615) 0.329
hsa-mir-196a2C>T
  TT 41 (24.3) 1.000 (Ref.) 39 (24.2) 1.000 (Ref.)
  TC 81 (47.9) 3.554 (1.296–9.747) 0.014 78 (48.5) 1.879 (0.767–4.603) 0.170
  CC 47 (27.8) 2.089 (0.642–6.798) 0.224 44 (27.3) 0.997 (0.345–2.885) 0.996
  TT 41 (24.3) 1.000 (Ref.) 39 (24.2) 1.000 (Ref.)
  TC/CC 128 (75.7) 3.093 (1.139–8.399) 0.028 122 (75.8) 1.558 (0.647–3.749) 0.325
  TT/TC 122 (72.2) 1.000 (Ref.) 117 (72.7) 1.000 (Ref.)
  CC 47 (27.8) 0.780 (0.347–1.750) 0.548 44 (27.3) 0.620 (0.280–1.372) 0.241
hsa-mir- 499A>G
  AA 102 (60.4) 1.000 (Ref.) 98 (60.9) 1.000 (Ref.)
  AG 62 (36.6) 0.829 (0.409–1.680) 0.605 58 (36.0) 0.722 (0.345–1.513) 0.391
  GG 5 (3.0) 1.206 (0.159–9.152) 0.857 5 (3.1) 1.085 (0.142–8.266) 0.938
  AA 102 (60.4) 1.000 (Ref.) 98 (60.9) 1.000 (Ref.)
  AG/GG 67 (39.6) 0.853 (0.430–1.691) 0.650 63 (39.1) 0.744 (0.364–1.524) 0.422
  AA/AG 164 (97.0) 1.000 (Ref.) 156 (96.9) 1.000 (Ref.)
  GG 5 (3.0) 1.268 (0.168–9.553) 0.819 5 (3.1) 1.208 (0.160–9.100) 0.855

OS, overall survival; RFS, relapse-free survival; HR, hazard ratio.

Percentage of patients adjusted for age, gender, tumor site, differentiation, chemotherapy and stage.